301 related articles for article (PubMed ID: 25596269)
1. Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia.
Origa R; Cazzola M; Mereu E; Danjou F; Barella S; Giagu N; Galanello R; Swinkels DW
Haematologica; 2015 May; 100(5):e169-71. PubMed ID: 25596269
[No Abstract] [Full Text] [Related]
2. Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait.
Jones E; Pasricha SR; Allen A; Evans P; Fisher CA; Wray K; Premawardhena A; Bandara D; Perera A; Webster C; Sturges P; Olivieri NF; St Pierre T; Armitage AE; Porter JB; Weatherall DJ; Drakesmith H
Blood; 2015 Jan; 125(5):873-80. PubMed ID: 25519750
[TBL] [Abstract][Full Text] [Related]
3. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
[TBL] [Abstract][Full Text] [Related]
4. Hepcidin independent iron recycling in a mouse model of β-thalassaemia intermedia.
Frazer DM; Wilkins SJ; Mirciov CS; Dunn LA; Anderson GJ
Br J Haematol; 2016 Oct; 175(2):308-317. PubMed ID: 27410488
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Glycosylation Profiles of Serum Glycoprotein from Iron Overload Thalassemia.
Huang A; Huang C; Zhang M; Zhu X; Qin X
Clin Lab; 2018 Jul; 64(7):1279-1287. PubMed ID: 30146840
[TBL] [Abstract][Full Text] [Related]
6. Iron Status in Newly Diagnosed
Susanah S; Rakhmilla LE; Ghozali M; Trisaputra JO; Moestopo O; Sribudiani Y; Idjradinata PS; Maskoen AM
Biomed Res Int; 2021; 2021():5560319. PubMed ID: 33954177
[TBL] [Abstract][Full Text] [Related]
7. Serum Hepcidin as a Diagnostic Marker of Severe Iron Overload in Beta-thalassemia Major.
Kaddah AM; Abdel-Salam A; Farhan MS; Ragab R
Indian J Pediatr; 2017 Oct; 84(10):745-750. PubMed ID: 28600663
[TBL] [Abstract][Full Text] [Related]
8. Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.
Schmidt PJ; Fleming MD
Hematol Oncol Clin North Am; 2014 Apr; 28(2):387-401. PubMed ID: 24589273
[TBL] [Abstract][Full Text] [Related]
9. Imbalance of erythropoiesis and iron metabolism in patients with thalassemia.
Huang Y; Lei Y; Liu R; Liu J; Yang G; Xiang Z; Liang Y; Lai Y
Int J Med Sci; 2019; 16(2):302-310. PubMed ID: 30745811
[No Abstract] [Full Text] [Related]
10. Stimulated erythropoiesis with secondary iron loading leads to a decrease in hepcidin despite an increase in bone morphogenetic protein 6 expression.
Frazer DM; Wilkins SJ; Darshan D; Badrick AC; McLaren GD; Anderson GJ
Br J Haematol; 2012 Jun; 157(5):615-26. PubMed ID: 22449175
[TBL] [Abstract][Full Text] [Related]
11. Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis C virus infection.
Hendy OM; Allam M; Allam A; Attia MH; El Taher S; Eldin MM; Ali A
Egypt J Immunol; 2010; 17(2):33-44. PubMed ID: 23082485
[TBL] [Abstract][Full Text] [Related]
12. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.
Gardenghi S; Ramos P; Marongiu MF; Melchiori L; Breda L; Guy E; Muirhead K; Rao N; Roy CN; Andrews NC; Nemeth E; Follenzi A; An X; Mohandas N; Ginzburg Y; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S
J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112
[TBL] [Abstract][Full Text] [Related]
13. Exogenous iron increases hemoglobin in beta-thalassemic mice.
Ginzburg YZ; Rybicki AC; Suzuka SM; Hall CB; Breuer W; Cabantchik ZI; Bouhassira EE; Fabry ME; Nagel RL
Exp Hematol; 2009 Feb; 37(2):172-83. PubMed ID: 19059700
[TBL] [Abstract][Full Text] [Related]
14. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
Porter JB; Cappellini MD; Kattamis A; Viprakasit V; Musallam KM; Zhu Z; Taher AT
Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462
[TBL] [Abstract][Full Text] [Related]
15. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study.
Pasricha SR; Frazer DM; Bowden DK; Anderson GJ
Blood; 2013 Jul; 122(1):124-33. PubMed ID: 23656728
[TBL] [Abstract][Full Text] [Related]
16. [Current management of thalassemia intermedia].
Thuret I
Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
[TBL] [Abstract][Full Text] [Related]
17. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.
Ginzburg Y; Rivella S
Blood; 2011 Oct; 118(16):4321-30. PubMed ID: 21768301
[TBL] [Abstract][Full Text] [Related]
18. Erythropoiesis-driven regulation of hepcidin in human red cell disorders is better reflected through concentrations of soluble transferrin receptor rather than growth differentiation factor 15.
Fertrin KY; Lanaro C; Franco-Penteado CF; de Albuquerque DM; de Mello MR; Pallis FR; Bezerra MA; Hatzlhofer BL; Olbina G; Saad ST; da Silva Araújo A; Westerman M; Costa FF
Am J Hematol; 2014 Apr; 89(4):385-90. PubMed ID: 24860871
[TBL] [Abstract][Full Text] [Related]
19. Identification of erythroferrone as an erythroid regulator of iron metabolism.
Kautz L; Jung G; Valore EV; Rivella S; Nemeth E; Ganz T
Nat Genet; 2014 Jul; 46(7):678-84. PubMed ID: 24880340
[TBL] [Abstract][Full Text] [Related]
20. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.
Gardenghi S; Marongiu MF; Ramos P; Guy E; Breda L; Chadburn A; Liu Y; Amariglio N; Rechavi G; Rachmilewitz EA; Breuer W; Cabantchik ZI; Wrighting DM; Andrews NC; de Sousa M; Giardina PJ; Grady RW; Rivella S
Blood; 2007 Jun; 109(11):5027-35. PubMed ID: 17299088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
